References
- Ware LB, Matthay MA. The acute respiratory distress syndrome. N
Engl J Med 2000;342:1334–49.
- Cell Death & Differentiation COVID-19 infection: the
perspectives on immune responses Yufang Shi1, Ying Wang Changshun
Shao, Jianan Huang, Jianhe Gan, Xiaoping Huang, Enrico Bucci, Mauro
Piacentini, Giuseppe Ippolito, Gerry Melino
- Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating
peptide-1/ interleukin-8: a novel cytokine that activates
neutrophils. J Clin Invest 1989;84:1045–9.
- Standiford TJ, Rolfe MW, Kunkel SL, et al. Macrophage
inflammatory protein-1: expression in interstitial lung disease. J
Immunol 1993;151:2852–63.
- Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM.High bronchoalveolar levels of tumor necrosis factor and its
inhibitors, interkeukin-1, interferon, and elastase, in patients with
respiratory distress syndrome after trauma, shock, or sepsis . Am Rev
Respir Dis 1992;145:1016–22.
- Siler TM, Swierkosz JE, Hyers TM, Fowler AA, Webster RO.Immunoreactive interleukin-1 in bronchoalveolar lavage fluid of
high-risk patients and patients with the adult respiratory distress
syndrome. Exp Lung Res 1989;15:881–94.
- Goodman RB, Strieter RM, Martin DP, et al. Inflammatory cytokines
in patients with persistence of the acute respiratory distress
syndrome. Am J Respir Crit Care Med 1996;154:602–11.
- Park WY, Goodman RB, Steinberg KP, et al. Cytokine balance in
the lungs of patients with acute respiratory distress syndrome. Am J
Respir Crit Care Med 2001;164:1896–903.
- Donnelly SC, Strieter RM, Reid PT, et al. The association
between mortality rates and decreased concentrations of interleukin-10
and interleukin-1 receptor antagonist in the lung fluids of patients
with the adult respiratory distress syndrome. Ann Intern Med
1996;125:191–6.
- Arend WP, Joslin FG, Thompson RC, Hannum CH. An IL-1 inhibitor
from human monocytes: production and characterization of biologic
properties. J Immunol 1989;143:1851–8.
- Arend WP. Interleukin-1 receptor antagonist. Adv Immunol
1993;54:167–227.
- Burger D, Chicheportiche R, Giri JG, Dayer JM. The inhibitory
activity of human interleukin-1 receptor antagonist is enhanced by
type II interleukin-1 soluble receptor and hindered by type I
interleukin-1 soluble receptor. J Clin Invest 1995;96:38–41.
- Conti
P
Ronconi
GCaraffa
A
Gallenga
CE
Ross
RFrydas
I
Kritas
SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and
lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2):
anti-inflammatory strategies. Masters PS, Perlman, S (2013)
Coronaviridae. In: Knipe DM, Howley P (eds) Fields Virology.
Lippincott Williams and Wilkins, Philadelphia, PA, pp 825–858.
- THE LANCET Infectious Diseases Vol 3 November 2003 Effects of
chloroquine on viral infections: an old drug against today’s
diseases? Andrea Savarino, Johan R Boelaert, Antonio Cassone,
Giancarlo Majori, and Roberto Cauda.
- J.Benhamou,
Ori-Michael; Geva,
Shahar; Jacobs,
Miriam; Drew,
Jonathan; Waldman,
Maor; Kalchiem-Dekel, The Use of Colchicine in Respiratory
DiseasesOr
Current
Respiratory Medicine Reviews, Volume 9, Number 5, 2013, pp.
300-304(5)
- Front. Pharmacol., 16 August 2019 The Association Between Usage of
Colchicine and Pneumonia: A Nationwide, Population-Based Cohort Study
- ”Colchicine
Monograph for Professionals”. Drugs.com. American Society of
Health-System Pharmacists. Retrieved 27 March 2019.
- Schachner, Lawrence A.; Hansen,
Ronald C. (2011).Pediatric
Dermatology E-Book. Elsevier Health Sciences. p. 177.
ISBN 9780723436652.
- Hutchison, Stuart J. (2009).Pericardial
Diseases: Clinical Diagnostic Imaging Atlas with DVD. Elsevier
Health Sciences. p. 58.
ISBN 9781416052746.
- ”Colchicine
for acute gout: updated information about dosing and drug
interactions”. National Prescribing Service, Australia. 14 May 2010.
Archived from
the
original on 30 June 2012. Retrieved 14 May 2010.
- Dalbeth N, Lauterio TJ,
Wolfe HR (October 2014).”Mechanism
of action of colchicine in the treatment of gout”. Clinical
Therapeutics. 36 (10): 1465–79.
- Chen LX, Schumacher HR
(October 2008). ”Gout: an evidence-based review”. Journal of
Clinical Rheumatology. 14 (5 Suppl): S55-62.
- ”Colcrys
(colchicine, USP) tablets 0.6 mg. Drug Approval Package”. US Food
and Drug Administration. 17 February 2010. Retrieved 19 August 2018.
- ”Information
for Healthcare Professionals: New Safety Information for Colchicine
(marketed as Colcrys)”.
U.S.
Food and Drug Administration.
- Van Echteld I,
Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D (August 2014).”Colchicine for acute gout”. The Cochrane Database of
Systematic Reviews. 8 (8): CD006190.
- Alabed S, Cabello JB, Irving
GJ, Qintar M, Burls A (August 2014).”Colchicine
for pericarditis” . The Cochrane Database of Systematic Reviews.8 (8): CD010652.
- Portincasa P (2016).”Colchicine, Biologic Agents and More for the Treatment of
Familial Mediterranean Fever. The Old, the New, and the Rare”.Current Medicinal Chemistry. 23 (1): 60–86.